Bio-Reference Laboratories (NASDAQ:BRLI) Could Grow Market Share

A number of factors in the industry are working together to help Bio-Reference Laboratories (NASDAQ:BRLI) grow market share if they can execute properly.

Jefferies (NYSE:JEF) said, "we expect BRLI to capitalize on its strengths in Genetics and Women's Health as well as some of the instability in the competitive landscape, which should provide opportunity for additional market share gains."

For full year 2011 the revenue estimate for Bio-Reference Laboratories was raised from $517.3 million to $528.5 million.

Jefferies reiterates a "Hold" rating on Bio-Reference Laboratories, which closed Friday at $21.43, up $0.35, or 1.66 percent. Jefferies raised their price target on them from $22 to $23.